ICAN, International Cancer Advocacy Network, is a Platinum-rated 501(c)(3) charitable organization specializing in direct navigation of Stage IV cancer patients, offering second opinion referrals, molecular profiling/comprehensive biomarker testing connections, clinical trials matching services, and early access/compassionate use matching services. In December 2023, ICAN was ranked fourth in the nation by Great Nonprofits in its Top-Rated Nonprofit Campaign (Cancer) in terms of highest rated and most rated cancer organizations. ICAN has three goals in assisting patients and their care partners: 1) optimize survival; 2) emphasize quality of life; and 3) embark on "no regrets" journey with the confidence that key issues will not be overlooked. The Exon 20 Group is a multi-stakeholder global coalition (72 countries) consisting of patients, care partners, thoracic oncologists and community oncologists, scientists, molecular pathologists, molecular profiling laboratory leadership, and pharma, biotech, and CRO leadership. The Exon 20 Group is a special organization under the auspices of ICAN, focusing on pan-tumor EGFR exon 20 insertion mutations and HER2 exon 20 insertion mutations which are diagnosed in 25 plus cancer types and affect patients from infancy, childhood through the nineties. The patient population features predominantly never smokers, women, and those of Asian heritage. The Exon 20 Group offers second opinion referrals, clinical trials matching and expanded access matching services, and emphasizes molecular testing at relevant pivot points. The Group provides an Angel Buddy Program with peer-to-peer counseling, oncology nursing services, virtual meetings, and 20 social media sites strictly for patients and their care partners. The group's Exon 20 International Research Consortium fosters collaborative projects between physician-scientists and leading laboratories. The work of the Ex 20 IRC is likely to impact other cancer types as well. ICAN also now owns and manages the MET Crusaders and the Biomarker Collaborative, in memory of their founder/co-founder John Hallick, of blessed memory. The MET Crusaders is a multi-stakeholder international support organization which handles MET exon 14, MET amplified, and MET over-expression patients in the U.S. and around the world. https://metcrusaders.org The Biomarker Collaborative is an international multi-stakeholder coalition of biomarker groups pan-heme and pan-tumor. https://biomarkercollaborative.org The fourth organization under the ICAN umbrella is the PD-L1 Amplifieds, https://pdl1amplifieds.org for patients with PD-L1 amplification (CD274 positive) which is found only by molecular profiling laboratories that deploy NGS, next-generation sequencing. One can be PD-L1 zero by IHC or PD-L1 low by IHC (immunohistochemistry) and nonetheless be PD-L1 amplified and perhaps can do well on checkpoint blockade. ICAN and the organizations under its umbrella specialize in protocol review, informed consent review, and clinical trials accrual and retention. Just to clarify, our NTEE codes are E01, G01, G30, and H30. We have never been a private T22 foundation, so that is an IRS error.

We strive to have every cancer patient and care partner have no regrets about therapeutic pathways e

Goal One: Increase the reach of our Patient Services.

Goal Two: Increase the reach of our global multi-stakeholder coalition, the Exon 20 Group, which focuses on rare EGFR exon 20 insertion mutations and HER2 exon 20 insertion mutations into chronic diseases.

Goal Three: Defeat any state legislation which would compromise patient-oncologist "shared decision-making" or which would deny any access to the most appropriate molecular diagnostics, imaging, and/or therapies.

Since 2008, our CEO has mentored other CEOs, board members, and/or staff of other 501(c)(3) organizations on board governance issues, strategic planning, and board-staff issues. We allow our CEO time to do that where needed. Our CEO and our director of governmental relations are recipients of professional development grants. Our ICAN research team leaders from time to time apply for special fellowships, and we fully support those efforts.

ICAN increased its collaborations and outreach with other rare cancer and pan-tumor organizations. We devoted more time to protocol review and clinical trial design issues. We added ten services for our Exon 20 Group patients and care partners. We greatly increased our social media reach in our Exon 20 Facebook and Inspire sites. At last count, 963 people (mostly oncologists across the globe) follow us on Twitter @Exon20Group. We increased the number of connections we have on linkedin.com to more than 3000 (mostly scientists, clinicians, and pharma and biotech executives). We had more time to deal with cancer media and with survey research companies profiling our patient populations. We emphasized ad hoc molecular tumor board expertise where needed. Many of ICAN's operations have been virtual since 1999 because we were greatly influenced in the early years by our treasurer Carolyn Sechler, CPA who was among the first national experts in virtual communications for 501(c)(3) organizations. That said we joined the rest of the world in embracing every manner of virtual meeting platform in order to deal as efficiently and effectively as possible with ICAN's clients, leadership, external collaborators, and professional medical and scientific advisors. In the last year, we entered into more collaborations than ever before. As Vice President of the Biomarker Collaborative, a consortium of leading organizations that are pan-tumor, our CEO played a part in an historic collaboration between the Biomarker Collaborative and the prominent comprehensive biomarker testing/molecular profiling laboratory, NeoGenomics. That collaboration which began in May 2021 was formally announced on January 24, 2022. For the first time, a clinician and patient receiving a molecular profiling report will be directed to the relevant cancer organization that assists patients and care partners dealing with a particular biomarker.